- Previous Close
32.38 - Open
33.30 - Bid 32.63 x --
- Ask 32.64 x --
- Day's Range
32.17 - 32.95 - 52 Week Range
25.96 - 39.15 - Volume
11,202,335 - Avg. Volume
13,493,518 - Market Cap (intraday)
57.242B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
17.83 - EPS (TTM)
1.83 - Earnings Date --
- Forward Dividend & Yield 0.93 (2.85%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
42.99
Huadong Medicine Co., Ltd produces and sells various pharmaceutical products in China. It also engages in the production and management of traditional Chinese and western raw medicines and preparations, and health care products; wholesale of TCM materials, TCM decoction pieces, chemical preparations, etc.; warehousing and storage business; and research, development, production, and sale of aesthetic medicine products. Huadong Medicine Co. Ltd. has strategic cooperation agreement with SynerK PharmaTech (Suzhou) Co. Ltd. to develop the small nucleic acid (siRNA) drug SNK-2726, an angiotensinogen (AGT) for the treatment of hypertension. Huadong Medicine Co., Ltd was founded in 1993 and is headquartered in Hangzhou, China.
www.eastchinapharm.com16,969
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000963.SZ
View MorePerformance Overview: 000963.SZ
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000963.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000963.SZ
View MoreValuation Measures
Market Cap
57.24B
Enterprise Value
54.87B
Trailing P/E
17.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.37
Price/Book (mrq)
2.60
Enterprise Value/Revenue
1.32
Enterprise Value/EBITDA
13.62
Financial Highlights
Profitability and Income Statement
Profit Margin
7.70%
Return on Assets (ttm)
6.71%
Return on Equity (ttm)
14.78%
Revenue (ttm)
41.71B
Net Income Avi to Common (ttm)
3.21B
Diluted EPS (ttm)
1.83
Balance Sheet and Cash Flow
Total Cash (mrq)
4.74B
Total Debt/Equity (mrq)
10.49%
Levered Free Cash Flow (ttm)
2.04B